Cefdinir for Oral Suspension USP, 250mg/5mL, packaged in a) 60mL (NDC 68180-723-20), b)100mL (NDC...

FDA Drug Recall #D-0376-2019 — Class II — January 2, 2019

Recall Summary

Recall Number D-0376-2019
Classification Class II — Moderate risk
Date Initiated January 2, 2019
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Lupin Pharmaceuticals Inc.
Location Baltimore, MD
Product Type Drugs
Quantity 287,784 bottles

Product Description

Cefdinir for Oral Suspension USP, 250mg/5mL, packaged in a) 60mL (NDC 68180-723-20), b)100mL (NDC 68180-723-10), Rx Only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, MD 21202; Manufactured by: Lupin Limited Mandideep 462 046 INDIA

Reason for Recall

CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.

Distribution Pattern

Nationwide within the United States

Lot / Code Information

a) Lot #: F700343, F700344, F700345, F700346, F700347,F700376, F700377, F700415, F700146,F700417, F700418, Exp. Jan 2019; F700419, F700420, F700492, F700493,F700508,F700665, Exp. February 2019; F700784, Exp. April 2019; b) Lot #: F700324, F700325, F700326, Exp. January 2019; F700618, F700619, F700620, Exp. February 2019.

Other Recalls from Lupin Pharmaceuticals Inc.

Recall # Classification Product Date
D-0541-2026 Class II Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx... Apr 24, 2026
D-0220-2026 Class II Ganirelix Acetate Injection, 250 mcg/0.5mL, Sin... Nov 13, 2025
D-0227-2026 Class II Sertraline Hydrochloride Tablets USP, 100 mg, 9... Nov 5, 2025
D-0542-2025 Class II Amlodipine and Benazepril HCl Capsules USP 2.5 ... Jul 2, 2025
D-0537-2025 Class II clomiPRAMINE Hydrochloride Capsules USP 25 mg, ... Jun 27, 2025

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.